ClinicalTrials.gg
CompletedNCT03737474Updated Apr 29, 2024Results posted

A Long-Term Study of Brexpiprazole in Patients With Major Depressive Disorder

A Phase 3 interventional study of Brexpiprazole in Major Depressive Disorder, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-04-29.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
248
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing brexpiprazole in Depressive Disorder, Major — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Depressive Disorder, Major.

Enrollment
12th of 24
248 · median 189
Started
2018
with 3 others
Phase 3
16 of 24
none open now
Registered
20th of 24
by date
Lead sponsor
2 of 24
Otsuka Pharmaceutical Co., Ltd.

Among the 24 studies testing brexpiprazole in Depressive Disorder, Major, this one is the 12th largest by enrollment, is one of 4 that started in 2018, is one of 16 in phase 3, and was the 20th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 24 studies testing brexpiprazole in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About brexpiprazole

brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing brexpiprazole in Depressive Disorder, Major, or all of them as a file.
02

Study summary

This trial is a 52-week study to assess the safety of long-term use of brexpiprazole as adjunctive therapy in combination with an antidepressant.

03

Conditions studied

  • Major Depressive Disorder
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Rollover subjects

    1. Outpatients
    2. Subjects who have completed the double-blind period of the double-blind trial and can commence the treatment period of this trial within 28 days from the completionof the double-blind period of the double-blind trial
    3. Subjects who have a level of comprehension sufficient to allow them to give written to all of the observation/examination/evaluation items specified in the protocol, and who can understand the contents of the trial
    4. Subjects with a classification-based diagnosis of "major depressive disorder, single episode" or "major depressive disorder, recurrent episode"
  • New subjects

    1. Outpatients
    2. Male and female patients ≥ 65 years of age (at the time of informed consent)
    3. Subjects who have a level of comprehension sufficient to allow them to give written informed consent to all of the observation/examination/evaluation items specified in the protocol, and who can understand the contents of the trial
    4. Patients with a DSM-5 classification-based diagnosis of "major depressive disorder, single episode" or "major depressive disorder, recurrent episode" whose current episode has persisted for at least 8 weeks

Exclusion criteria

Exclusion Criteria:

  • Rollover subjects

    1. Female subjects who are pregnant or breastfeeding or who have positive pregnancy test (urine) results at baseline
    2. Sexually active male subjects or sexually active female subjects of , who will not agree to practice 2 different methods of or to remain abstinent during the trial and for 30 days after the final IMP administration. For birth control, 2 of the following methods must be used: vasectomy, tubal ligation, vaginal diaphragm, intra-uterine contraceptive device (IUD), oral contraceptives, or condom with spermicide.
    3. Subjects who experience a change to the manic state in the antidepressant treatment period of the double-blind trial
    4. Subjects who are discovered to not meet the inclusion criteria or to fall under any of the exclusion criteria in the doubleblind trial
    5. Subjects who showed marked noncompliance with the IMP treatment in the double-blind trial (subjects whose IMP compliance rates are \< 65% between prescribed visits)
  • New subjects

    1. Sexually active male subjects who will not agree to practice 2different methods of birth control or to remain abstinent during the trial and for 30 days after the final IMP administration. For birth control, 2 of the following methods must be used: vasectomy, tubal ligation, vaginal diaphragm, intra-uterine contraceptive device (IUD), oral contraceptives, or condom with spermicide.
    2. Patients with a treatment history showing that all antidepressants (also including those not used for the current major depressive episode) cannot be tolerated
    3. Patients with a history of electroconvulsive therapy
    4. Patients with a diagnosis of any of the following diseases according to

      1. Neurocognitive disorders
      2. Schizophrenia spectrum and other psychotic disorders
      3. Bipolar and related disorders
      4. Feeding and eating disorders
      5. Obsessive-compulsive disorder
      6. Panic disorder
      7. Posttraumatic stress disorder
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
248 participants (actual)

Study arms

  • Experimental
    Brexpiprazole

    2 mg/day (starting dose 1mg/day) of Brexpiprazole will be orally administered once daily

    Drug: Brexpiprazole

Interventions

  • 2 mg/day (starting dose 1mg/day) of Brexpiprazole will be orally administered once daily

06

What researchers measure

Primary outcomes

  1. The Frequency of Subjects With Treatment-Emergent Adverse Events (TEAEs)

    A treatment-emergent adverse event (TEAE) was defined as an AE that started after start of investigational medicinal product (IMP) treatment.

    Time frame: From baseline to week 52

Secondary outcomes

  1. Mean Changes From Baseline in Montgomery Åsberg Depression Rating Scale(MADRS) Total Scores at Week 52(LOCF)

    The MADRS was a clinician-rated scale which evaluated the level of depression.The MADRS consists of 10 items assessed apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thought. Each item was scored from 0 to 6, with higher scores indicating worse condition. Summed subscales were combined to compute a total score. Total score ranges from 0 to 60, with higher scores indicating worse condition.

    Time frame: Baseline and Week 52(LOCF)

  2. The Proportion of Subjects Who Score 1 or 2 on the Clinical Global Impression-Improvement(CGI-I) Scale at Week 52(LOCF)

    The CGI-I Scale was clinician-rated scale which assessed the total improvement of the patient's condition compared to that at baseline. Scores range from 0 to 7: 0 = Not assessed, 1= Very much improved, 2 = Much improved, 3= Minimally improved, 4= No change, 5= Minimally worse, 6= Much worse, 7= Very much worse. Higher scores indicate worse condition.

    Time frame: Baseline and Week 52 (LOCF)

  3. Mean Changes From Baseline in Clinical Global Impression-Severity of Illness(CGI-S) at Week 52(LOCF)

    The CGI-S Scale was a clinician-rated scale which assessed how mentally ill the patient is at the time. Scores range from 0 to 7: 0 = Not assessed, 1= Normal, not at all ill, 2 =Borderline mentally ill, 3= Mildly ill, 4= Moderately ill, 5= Markedly ill, 6= Severely ill, 7= Among the most extremely ill patients. Higher scores indicate worse condition.

    Time frame: Baseline and Week 52 (LOCF)

  4. Mean Changes From Baseline in Hamiliton Depression Rating Scale(HAM-D) Item Total Scores at Week 52(LOCF)

    The HAM-D was a clinician-rated scale which evaluated the level of depression. The HAM-D consists of 17 items such as depression mood, feeling of guilt, suicide, insomnia, work and activities, retardation, and so on. Each item was scored from 0 to 2, 3 or 4, with higher scores indicating worse condition. Summed subscales were combined to compute a total score. Total score ranges from 0 to 53 , with higher score indicating worse condition.

    Time frame: Baseline and Week 52 (LOCF)

  5. Mean Changes From Baseline in Sheehan Disability Scale (SDS) Scores at Week 52(LOCF)

    SDS Scale was a patient-rated scale which assessed the degree of impairment for each of 3 items ("work/school," "social life," and "family life/home responsibilities") on a 11-point scale ranging from 0 to 10. The mean SDS score was the mean of scores for 3 items. Higher scores indicate worse condition.

    Time frame: Baseline and Week 52 (LOCF)

07

Results

Posted Apr 29, 2024

Participant flow

This trial was conducted in 248 participants in Japan. Of the 248 subjects who were administered investigational medicinal product, the efficacy analysis set and the safety analysis set comprised 247 subjects (216 rollover subjects, 31 newly enrolled subjects) of the total brexpiprazole population.

Participant flow — Overall Study
MilestoneNew SubjectsRollover Subjects
Started31216
Completed6132
Not completed2584
Withdrew: Adverse event1848
Withdrew: Lack of efficacy13
Withdrew: Protocol violation08
Withdrew: Withdrawal by subject520
Withdrew: Non-compliance with study drug01
Withdrew: Physician decision14

Outcome measures

PrimaryThe Frequency of Subjects With Treatment-Emergent Adverse Events (TEAEs)

A treatment-emergent adverse event (TEAE) was defined as an AE that started after start of investigational medicinal product (IMP) treatment.

Time frame:
From baseline to week 52
Reported as:
Number · percentage of participants
The Frequency of Subjects With Treatment-Emergent Adverse Events (TEAEs)
percentage of participantsNew SubjectsRollover Subjects
The Frequency of Subjects With Treatment-Emergent Adverse Events (TEAEs)96.893.1
SecondaryMean Changes From Baseline in Montgomery Åsberg Depression Rating Scale(MADRS) Total Scores at Week 52(LOCF)

The MADRS was a clinician-rated scale which evaluated the level of depression.The MADRS consists of 10 items assessed apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thought. Each item was scored from 0 to 6, with higher scores indicating worse condition. Summed subscales were combined to compute a total score. Total score ranges from 0 to 60, with higher scores indicating worse condition.

Time frame:
Baseline and Week 52(LOCF)
Reported as:
Mean · Units on a scale
Mean Changes From Baseline in Montgomery Åsberg Depression Rating Scale(MADRS) Total Scores at Week 52(LOCF)
Units on a scaleNew SubjectsRollover Subjects
Mean Changes From Baseline in Montgomery Åsberg Depression Rating Scale(MADRS) Total Scores at Week 52(LOCF)-2.8 ± 10.4-4.9 ± 9.0
SecondaryThe Proportion of Subjects Who Score 1 or 2 on the Clinical Global Impression-Improvement(CGI-I) Scale at Week 52(LOCF)

The CGI-I Scale was clinician-rated scale which assessed the total improvement of the patient's condition compared to that at baseline. Scores range from 0 to 7: 0 = Not assessed, 1= Very much improved, 2 = Much improved, 3= Minimally improved, 4= No change, 5= Minimally worse, 6= Much worse, 7= Very much worse. Higher scores indicate worse condition.

Time frame:
Baseline and Week 52 (LOCF)
Reported as:
Number · percentage of Participants
The Proportion of Subjects Who Score 1 or 2 on the Clinical Global Impression-Improvement(CGI-I) Scale at Week 52(LOCF)
percentage of ParticipantsNew SubjectsRollover Subjects
The Proportion of Subjects Who Score 1 or 2 on the Clinical Global Impression-Improvement(CGI-I) Scale at Week 52(LOCF)29.037.0
SecondaryMean Changes From Baseline in Clinical Global Impression-Severity of Illness(CGI-S) at Week 52(LOCF)

The CGI-S Scale was a clinician-rated scale which assessed how mentally ill the patient is at the time. Scores range from 0 to 7: 0 = Not assessed, 1= Normal, not at all ill, 2 =Borderline mentally ill, 3= Mildly ill, 4= Moderately ill, 5= Markedly ill, 6= Severely ill, 7= Among the most extremely ill patients. Higher scores indicate worse condition.

Time frame:
Baseline and Week 52 (LOCF)
Reported as:
Mean · units on a scale
Mean Changes From Baseline in Clinical Global Impression-Severity of Illness(CGI-S) at Week 52(LOCF)
units on a scaleNew SubjectsRollover Subjects
Mean Changes From Baseline in Clinical Global Impression-Severity of Illness(CGI-S) at Week 52(LOCF)-0.5 ± 1.3-0.5 ± 1.0
SecondaryMean Changes From Baseline in Hamiliton Depression Rating Scale(HAM-D) Item Total Scores at Week 52(LOCF)

The HAM-D was a clinician-rated scale which evaluated the level of depression. The HAM-D consists of 17 items such as depression mood, feeling of guilt, suicide, insomnia, work and activities, retardation, and so on. Each item was scored from 0 to 2, 3 or 4, with higher scores indicating worse condition. Summed subscales were combined to compute a total score. Total score ranges from 0 to 53 , with higher score indicating worse condition.

Time frame:
Baseline and Week 52 (LOCF)
Reported as:
Mean · units on a scale
Mean Changes From Baseline in Hamiliton Depression Rating Scale(HAM-D) Item Total Scores at Week 52(LOCF)
units on a scaleNew SubjectsRollover Subjects
Mean Changes From Baseline in Hamiliton Depression Rating Scale(HAM-D) Item Total Scores at Week 52(LOCF)-2.2 ± 8.3-4.1 ± 6.6
SecondaryMean Changes From Baseline in Sheehan Disability Scale (SDS) Scores at Week 52(LOCF)

SDS Scale was a patient-rated scale which assessed the degree of impairment for each of 3 items ("work/school," "social life," and "family life/home responsibilities") on a 11-point scale ranging from 0 to 10. The mean SDS score was the mean of scores for 3 items. Higher scores indicate worse condition.

Time frame:
Baseline and Week 52 (LOCF)
Reported as:
Mean · score on a scale
Mean Changes From Baseline in Sheehan Disability Scale (SDS) Scores at Week 52(LOCF)
score on a scaleNew SubjectsRollover Subjects
Mean Changes From Baseline in Sheehan Disability Scale (SDS) Scores at Week 52(LOCF)0.43 ± 2.48-0.61 ± 2.35

Adverse events

Collected over Adverse events were monitored from signing of the informed consent form until follow-up for up to 30 days (±5 days) after the final day of IMP administration (end of trial date [final day of observation]). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
New Subjects0/31 (0%)1/31 (3.2%)30/31 (96.8%)
Rollover Subjects1/216 (0.5%)8/216 (3.7%)201/216 (93.1%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventNew SubjectsRollover Subjects
Major depressionPsychiatric disorders1/310/216
Duodenal perforationGastrointestinal disorders0/311/216
DeathGeneral disorders0/311/216
AppendicitisInfections and infestations0/311/216
HIV infectionInfections and infestations0/311/216
Septic shockInfections and infestations0/311/216
Ligament sprainInjury, poisoning and procedural complications0/311/216
Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/311/216
Metastases to lymph nodesNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/311/216
Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/311/216
Most frequent other events
Showing 10 of 72
Most frequent other events
EventNew SubjectsRollover Subjects
AkathisiaNervous system disorders12/3146/216
Weight increasedInvestigations4/3178/216
NasopharyngitisInfections and infestations5/3147/216
TremorNervous system disorders6/3115/216
DyskinesiaNervous system disorders4/317/216
Extrapyramidal disorderNervous system disorders4/3112/216
SomnolenceNervous system disorders2/3124/216
HeadacheNervous system disorders1/3122/216
InsomniaPsychiatric disorders2/3122/216
PalpitationsCardiac disorders3/312/216

Baseline characteristics

This trial was conducted in 248 participants in Japan. Of the 248 subjects who were administered investigational medicinal product, the efficacy analysis set and the safety analysis set comprised 247 subjects (216 rollover subjects, 31 newly enrolled subjects) of the total brexpiprazole population.

Age, Categorical
Age, Categorical(Participants)New SubjectsRollover SubjectsTotal
<=18 years000
Between 18 and 65 years0216216
>=65 years31031
Age, Continuous
Age, Continuous(Years)New SubjectsRollover SubjectsTotal
Mean70.3 ± 4.540.7 ± 10.344.4 ± 13.9
Sex: Female, Male
Sex: Female, Male(Participants)New SubjectsRollover SubjectsTotal
Female1883101
Male13133146
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)New SubjectsRollover SubjectsTotal
Asian31216247
Region of Enrollment
Region of Enrollment(participants)New SubjectsRollover SubjectsTotal
Japan31216247
08

Study locations

1 site
  • Nanko-kokorono clinic
    Shirakawa, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article Publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Mar 2021, 29 months.

Results were first posted in Apr 2024, 3 years 1 month after primary completion.

Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 29 months is above that.

Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2018
First posted
Nov 9, 2018
StartActual
Oct 4, 2018
Primary completionActual
Mar 17, 2021
CompletionActual
Apr 13, 2021
Results first posted
Apr 29, 2024
Last update
Apr 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03737474
Responsible party
Sponsor
First posted
Nov 9, 2018
Start date
Oct 4, 2018
Primary completion
Mar 17, 2021
Completion
Apr 13, 2021
Results posted
Apr 29, 2024
Last update
Apr 29, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion